Vanguard Group Inc. decreased its position in Trupanion, Inc. (NASDAQ:TRUP - Free Report) by 0.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,572,305 shares of the financial services provider's stock after selling 24,420 shares during the period. Vanguard Group Inc. owned about 8.35% of Trupanion worth $133,140,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in TRUP. Quarry LP acquired a new stake in shares of Trupanion in the fourth quarter valued at about $39,000. Coppell Advisory Solutions LLC lifted its stake in shares of Trupanion by 58.3% in the fourth quarter. Coppell Advisory Solutions LLC now owns 1,249 shares of the financial services provider's stock valued at $61,000 after purchasing an additional 460 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Trupanion by 11.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,234 shares of the financial services provider's stock valued at $83,000 after purchasing an additional 235 shares during the period. Bayesian Capital Management LP acquired a new stake in shares of Trupanion in the fourth quarter valued at about $201,000. Finally, Eschler Asset Management LLP acquired a new stake in shares of Trupanion in the fourth quarter valued at about $214,000.
Analysts Set New Price Targets
Several analysts recently commented on TRUP shares. Piper Sandler raised their price objective on shares of Trupanion from $62.00 to $67.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Lake Street Capital reduced their price objective on shares of Trupanion from $65.00 to $60.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Stifel Nicolaus raised their price objective on shares of Trupanion from $41.00 to $45.00 and gave the company a "hold" rating in a research note on Friday, August 8th. Finally, Cantor Fitzgerald upgraded shares of Trupanion to a "hold" rating in a research report on Wednesday, August 13th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $54.17.
Check Out Our Latest Research Report on Trupanion
Insider Transactions at Trupanion
In other news, insider Brenna Mcgibney sold 2,390 shares of Trupanion stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $45.17, for a total transaction of $107,956.30. Following the completion of the sale, the insider directly owned 1,317 shares in the company, valued at $59,488.89. The trade was a 64.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Fawwad Qureshi sold 2,800 shares of Trupanion stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $45.56, for a total transaction of $127,568.00. Following the sale, the chief financial officer owned 6,451 shares of the company's stock, valued at approximately $293,907.56. This trade represents a 30.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,924 shares of company stock worth $559,256 over the last ninety days. 5.42% of the stock is currently owned by corporate insiders.
Trupanion Price Performance
TRUP traded down $0.11 during midday trading on Wednesday, reaching $46.35. 323,909 shares of the company's stock were exchanged, compared to its average volume of 576,930. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.69 and a quick ratio of 1.69. The stock has a market capitalization of $1.99 billion, a PE ratio of 178.28 and a beta of 1.78. The business's 50-day moving average price is $50.47 and its 200 day moving average price is $44.08. Trupanion, Inc. has a 1-year low of $31.00 and a 1-year high of $57.90.
Trupanion (NASDAQ:TRUP - Get Free Report) last announced its earnings results on Thursday, August 7th. The financial services provider reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.25. The company had revenue of $353.56 million during the quarter, compared to analysts' expectations of $346.73 million. Trupanion had a net margin of 0.81% and a return on equity of 3.31%. The firm's quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.14) earnings per share. Trupanion has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts anticipate that Trupanion, Inc. will post 0.13 EPS for the current fiscal year.
About Trupanion
(
Free Report)
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Featured Stories

Before you consider Trupanion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trupanion wasn't on the list.
While Trupanion currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.